natgillin/translations-raw huggingface dataset:
The inducing effect may persist for at least 2 weeks after cessation of treatment with St John's wort (see section 4.3). 
Indukcijski učinek lahko traja še vsaj 2 tedna po prenehanju zdravljenja s šentjanževko (glejte poglavje 4.3).
• you are allergic to lopinavir, ritonavir or any of the other ingredients of Kaletra (see section 6); • you have severe liver problems. 
- ste alergični na lopinavir, ritonavir ali katerokoli sestavino tega zdravila (navedeno v poglavju 6); - imate hude težave z jetri.
Kaletra should be used with caution in such patients (see section 5.1). 
Zdravilo Kaletra morate pri takšnih bolnikih uporabljati previdno (glejte poglavje 5.1).
Overdoses with Kaletra oral solution have been reported (including fatal outcome). 
Opisani so bili primeri prevelikega odmerjanja zdravila Kaletra peroralna raztopina (vključno s smrtnim izidom).
If the benefit is considered to outweigh the risk and Kaletra must be used, patients should be carefully monitored for safety. 
Če korist odtehta tveganje, je treba zdravilo Kaletra uporabiti in bolnika pozorno spremljati glede varnosti.
For volumes up to 2 ml. 
Za volumne do 2 ml.
Particular caution should be used when prescribing sildenafil or tadalafil for the treatment of erectile dysfunction in patients receiving Kaletra. 
Posebna previdnost je potrebna pri predpisovanju sildenafila ali tadalafila za zdravljenje erektilne disfunkcije bolnikom, ki dobivajo zdravilo Kaletra.
Clinical results 
KLINIČNI PODATKI
QD BID Difference [95% CI] 
Razlika [95 % IZ]
Antipsychotics/ Neuroleptics 
Antipsihotiki/nevroleptiki Lurasidon
Anxiety Uncommon Abnormal dreams, libido decreased 
Psihiatrične motnje pogosti anksioznost občasni nenormalne sanje, zmanjšan libido
Do not take Kaletra with any of the following medicines: 
Ne jemljite zdravila Kaletra, če trenutno jemljete katero od naslednjih zdravil:
Plasma concentrations of lopinavir were measured over four 12-hour periods during second trimester (20-24 weeks gestation), third trimester before dose increase (30 weeks gestation), third trimester after dose increase (32 weeks gestation), and at 8 weeks post-partum. 
Plazemske koncentracije lopinavirja so bile izmerjene v štirih 12-urih obdobjih med drugim trimesečjem (20 - 24 tednov gestacijske dobe), tretjim trimesečjem pred povečanjem odmerka (30 tednov gestacijske dobe), tretjim trimesečjem po povečanju odmerka (32 tednov gestacijske dobe) in pri 8 tednih po porodu.
Tell your doctor if you or your child experience 
Povejte svojemu zdravniku, če vi ali vaš otrok doživite kaj od naslednjega
Kaletra is administered orally and should always be taken with food (see section 5.2). 
Zdravilo Kaletra se jemlje peroralno in vedno s hrano (glejte poglavje 5.2).
Kaletra has been shown in vivo to induce its own metabolism and to increase the biotransformation of some medicinal products metabolised by cytochrome P450 enzymes (including CYP2C9 and CYP2C19) and by glucuronidation. 
In vivo je dokazano, da zdravilo Kaletra inducira svojo lastno presnovo in zvečuje biotransformacijo nekaterih zdravil, ki se presnavljajo z encimi citokroma P450 (vključno s CYP2C9 in CYP2C19) in z glukuronidacijo.
• decreased sexual desire; 
- zmanjšana želja po spolnosti; - vnetje ledvic;
Felodipine, Nifedipine, Nicardipine: 
Felodipin, nifedipin in nikardipin
Unsuitable in hereditary fructose intolerance. 
To je neprimerno pri podedovani intoleranci za fruktozo.
• The usual adult dose is 400 mg/100 mg twice a day i.e. every 12 hours, in combination with other anti-HIV medicines. 
- Običajni odmerek za odrasle je 400 mg/100 mg dvakrat na dan, to je vsakih 12 ur, v kombinaciji z drugimi zdravili proti HIV.
Fusidic acid used to treat long-term infections of the bones and joints may be taken under doctor's supervision (see Other medicines and Kaletra section); 
Fusidno kislino za zdravljenje dolgotrajnih okužb kosti in sklepov se sme uporabljati pod nadzorstvom zdravnika (glejte poglavje Druga zdravila in zdravilo Kaletra);
Adverse reactions from clinical trials and post-marketing experience in adult and paediatric patients: The following events have been identified as adverse reactions. 
Neželeni učinki v kliničnih študijah in iz obdobja trženja zdravila pri odraslih in pediatričnih bolnikih: Opisani so bili naslednji neželeni dogodki.
• Always keep enough Kaletra on hand so you don't run out. 
- Vedno imejte pri roki dovolj zdravila Kaletra, da vam je ne bo zmanjkalo.
The effects of Kaletra (in combination with other antiretroviral agents) on biological markers (plasma HIV RNA levels and CD4+ T-cell counts) have been investigated in controlled studies of Kaletra of 48 to 360 weeks duration. 
Učinke zdravila Kaletra (v kombinaciji z drugimi protiretrovirusnimi zdravili) na biološke označevalce (koncentracijo HIV RNA in število T-celic CD4 v plazmi) so raziskali v kontrolirani 48tedenski študiji zdravila Kaletra ter v dodatnih 360-tedenskih študijah zdravila Kaletra.
While rosuvastatin is poorly metabolised by CYP3A4, an increase of its plasma concentrations was observed. 
Ker se rosuvastatin slabo presnavlja s CYP3A4, so opažali zvišanje koncentracije v plazmi.
The effective (peak to trough) half-life of lopinavir over a 12 hour dosing interval averaged 5 − 6 hours, and the apparent oral clearance (CL/F) of lopinavir is 6 to 7 l/h. 
Efektivni (od vrha do dna) razpolovni čas lopinavirja v 12-urnem odmernem intervalu je bil v povprečju od 5 do 6 ur, navidezni peroralni očistek (CL/F) lopinavirja pa je 6 do 7 l/h.
In children 2 years of age and older, the nature of the safety profile is similar to that seen in adults (see Table in section b). 
d. Pediatrična populacija Pri otrocih, starih 2 leti in več, je varnostni profil podoben kot pri odraslih (glejte preglednico v razdelku b).
The study did not contain a control arm of patients not receiving Kaletra. 
Študija ni obsegala kontrolnega kraka bolnikov brez zdravila Kaletra.
In patients currently taking Kaletra and starting lamotrigine: no dose adjustments to the recommended dose escalation of lamotrigine should be necessary. 
Kaletra in pričnejo z uporabo lamotrigina: ni potrebno prilagajati odmerka na priporočeno povečanje odmerka lamotrigina.
At steady state, lopinavir protein binding remains constant over the range of observed concentrations after 400/100 mg Kaletra twice daily, and is similar between healthy volunteers and HIV-positive patients. 
V stanju dinamičnega ravnovesja ostaja vezava lopinavirja na beljakovine v območju opazovanih koncentracij po 400/100 mg zdravila Kaletra dvakrat na dan stalna ter je pri zdravih prostovoljcih in pri HIV-pozitivnih bolnikih podobna.
The EC50 of lopinavir against the 56 baseline viral isolates ranged from 0.6 to 96-fold higher than the EC50 against wild type HIV. 
EC50 lopinavirja proti 56 izhodiščnim virusnim izolatom je bila od 0,6- do 96-krat večja kot EC50 proti divjemu tipu HIV.
If this co-administration is judged unavoidable, increased dose of Kaletra at 400 mg/400 mg twice daily may be administered with rifampicin under close safety and therapeutic drug monitoring. 
Če je takšna sočasna uporaba neizogibna, je mogoče večji odmerek zdravila Kaletra 400 mg/400 mg dvakrat na dan uporabiti z rifampicinom ob natančnem spremljanju varnosti in terapevtskem spremljanju koncentracij zdravil.
Turn the syringe so that the tip is pointing up, gently tap it and push plunger to remove any air bubbles. 
Brizgo obrnite, tako da konica gleda navzgor in nežno potrkajte po njej ter potisnite bat, da odstranite morebitne zračne mehurčke.
Based on BSA (mg/m2)* 
Na podlagi telesne površine (mg/m2)*
• If a side effect is preventing you from taking Kaletra as directed tell your doctor right away. 
- Če vam neželen učinek prepreči, da bi zdravilo Kaletra jemali, kot je naročeno, to takoj povejte zdravniku.
• Breast-feeding mothers should not take Kaletra unless specifically directed by the doctor. 
- Doječe matere ne smejo jemati zdravila Kaletra, razen če jim tega posebej ne naroči zdravnik.
What you need to know before you or your child takes Kaletra Do not take Kaletra if: 
Kaj morate vedeti, preden boste vi ali vaš otrok vzeli zdravilo Kaletra Ne jemljite zdravila Kaletra če:
Repeat-dose toxicity studies in rodents and dogs identified major target organs as the liver, kidney, thyroid, spleen and circulating red blood cells. 
Študije toksičnosti pri ponavljajočih odmerkih pri glodalcih in psih so pokazale, da so glavni ciljni organi jetra, ledvice, ščitnica, vranica in krožeče rdeče krvne celice.
Kaletra does not inhibit CYP2D6, CYP2C9, CYP2C19, CYP2E1, CYP2B6 or CYP1A2 at clinically relevant concentrations (see section 4.3). 
CYP2C19, CYP2E1, CYP2B6 ali CYP1A2 (glejte poglavje 4.3).
Experienced patients received nevirapine plus up to two nucleoside reverse transcriptase inhibitors. 
Izkušeni bolniki so dobili nevirapin ter do dva nukleozidna zaviralca reverzne transkriptaze.
Dosing should be less than 5 ml twice daily for children weighing less than 40 kg. 
Za otroke, ki tehtajo manj kot 40 kg, mora biti odmerek manjši od 5 ml dvakrat na dan.
Based on the findings in a paediatric study (observed exposures were approximately 35% AUC12 and 75% lower Cmin than in adults), young children from 14 days to 3 months could have sub-optimal exposure with a potential risk of inadequate virologic suppression and emergence of resistance (see section 5.2). 
35 % AUC12 in 75 % nižje Cmin kot pri odraslih) bi mladi otroci, stari od 14 dni do 3 mesecev, lahko imeli suboptimalno izpostavljenost z možnim tveganjem za nezadostno virološko zavrtje in pojav rezistence (glejte poglavje 5.2).
If a child is unable to reliably swallow a Kaletra tablet, Kaletra oral solution formulation should be prescribed. 
Če otrok ne zmore zanesljivo pogoltniti tablete zdravila Kaletra, mu morate predpisati peroralno raztopino zdravila Kaletra.
The following side effects have been reported by patients who took this medicine. 
Bolniki, ki so jemali to zdravilo, so poročali o naslednjih neželenih učinkih.
Total amounts of alcohol and propylene glycol from all medicines, including Kaletra oral solution, that are to be given to infants should be taken into account in order to avoid toxicity from these excipients (see section 4.4). 
Upoštevati je treba celokupno količino alkohola in propilenglikola v vseh zdravilih, ki jih bo prejel dojenček, vključno z zdravilom Kaletra peroralna raztopina, da bi se izognili toksičnosti teh pomožnih snovi (glejte poglavje 4.4).
• Haemophilia type A and B as Kaletra might increase the risk of bleeding. 
- hemofilijo tipa A in B, ker zdravilo Kaletra lahko zviša tveganje za krvavitve.
AUC12 (µg•h/ml) Age ≥ 14 days to < 6 weeks cohort (N = 9): 
AUC12 (µg•h/ml) Kohorta, v kateri je bila starost ≥ 14 dni do < 6 tednov (N = 9):
Co-administration of delamanid with a strong inhibitor of CYP3A (as lopinavir/ritonavir) may increase exposure to delamanid metabolite, which has been associated with QTc prolongation. 
Sočasna uporaba delamanida z močnim zaviralcem CYP3A (kot je lopinavir/ritonavir) lahko poveča izpostavljenost presnovku delamanida, ki ga povezujejo s podaljšanjem intervala QTc.
However, if the benefit outweighs the risk, co-administration of bedaquiline with lopinavir/ritonavir must be done with caution. 
Vendar pa je, če je korist večja od tveganja, pri sočasni uporabi bedakilina z lopinavirjem/ritonavirjem potrebna previdnost.
Monitoring plasma concentrations of methadone is recommended. 
Priporočljivo je kontrolirati koncentracijo metadona v plazmi.
Before prescribing Kaletra 100/25 mg tablets, infants and young children should be assessed for the ability to swallow intact tablets. 
Preden predpišete tablete zdravila Kaletra 100/25 mg, morate pri dojenčkih in majhnih otrocih oceniti, ali zmorejo pogoltniti cele tablete.
Kaletra contains 42% v/v alcohol. 
Zdravilo Kaletra vsebuje 42 % v/v alkohola.
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness: very common (≥1/10), common (≥ 1/100 
V razvrstitvah pogostnosti so neželeni učinki navedeni po padajoči resnosti: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1000 do < 1/100) in neznani
Marked triglyceride elevation is a risk factor for development of pancreatitis. 
Izrazito zvišanje trigliceridov je dejavnik tveganja za pankreatitis.
At week 48, the efficacy and safety with twice-daily dosing (n=87) in the paediatric population given lopinavir/ritonavir 100 mg/25 mg tablets was consistent with the efficacy and safety findings in previous adult and paediatric studies using lopinavir/ritonavir twice daily. 
V 48. tednu sta bili učinkovitost in varnost odmerjanja dvakrat na dan v pediatrični populaciji (n=87), ki je prejemala lopinavir/ritonavir 100 mg/25 mg tablete skladni z ugotovitvami o učinkovitosti in varnosti pri predhodnih študijah pri odraslih in otrocih, kjer so uporabljali kombinacijo lopinavir/ritonavir dvakrat na dan.
In contrast, similar concentrations of lopinavir/ritonavir demonstrated no repolarisation delay in the canine cardiac Purkinje fibres. 
Nasprotno pa podobne koncentracije lopinavirja/ritonavirja niso upočasnile repolarizacije v Purkinjejevih vlaknih srca psov.
Only at high inadvertent doses, it can cause headache and gastrointestinal upset. 
Le v velikih, nenamernih odmerkih lahko povzroči glavobol in prebavne motnje.
When co-administered with Kaletra, sildenafil doses must not exceed 25 mg in 48 hours and tadalafil doses must not exceed 10 mg every 72 hours. 
Med sočasno uporabo z zdravilom Kaletra odmerek sildenafila ne sme preseči 25 mg v 48 urah in odmerek tadalafila ne 10 mg na 72 ur.
• Muscle pain, tenderness or weakness, particularly in combination with these medicines. 
- Bolečine, občutljivost ali šibkost mišic, zlasti v kombinaciji s protiretrovirusnimi zdravili.
3rd Trimester n = 23 
3. trimesečje n = 23
Lopinavir is essentially completely metabolised by CYP3A. 
Lopinavir se v bistvu popolnoma presnovi s CYP3A.
Instead, contact your doctor. 
V takem primeru se posvetujte z zdravnikom.
Because lopinavir and ritonavir are highly protein bound, it is unlikely that they will be significantly removed by haemodialysis or peritoneal dialysis. 
Ker sta lopinavir in ritonavir v veliki meri vezana na beljakovine, ni verjetno, da bi ju hemodializa ali peritonealna dializa odstranila v pomembni meri.
Activity of other protease inhibitors against isolates that developed incremental resistance to lopinavir after Kaletra therapy in protease inhibitor experienced patients: The presence of cross resistance to other protease inhibitors was analysed in 18 rebound isolates that had demonstrated evolution of resistance to lopinavir during 3 Phase II and one Phase III studies of Kaletra in protease inhibitorexperienced patients. 
Dejavnost drugih zaviralcev proteaz proti izolatom, ki so razvili naraščajočo odpornost proti lopinavirju po zdravljenju z zdravilom Kaletra pri bolnikih, izkušenih z zaviralci proteaz: Obstoj navzkrižne odpornosti proti drugim zaviralcem proteaz so analizirali v 18 izolatih s preobratom; razvoj odpornosti proti lopinavirju so ugotovili med tremi študijami zdravila Kaletra II.
Place the dosing syringe in your child's mouth towards the cheek and gently push the plunger down to release the medicine. 
Brizgo za peroralno dajanje vstavite otroku v usta v smeri proti licu in nežno potisnite bat navzdol, da zdravilo izteče.
Pharmacokinetic differences due to race have not been identified. 
Prav tako niso ugotovili farmakokinetičnih razlik zaradi rase.
Fluvastatin or Pravastatin 
Fluvastatin ali pravastatin
Not all pack sizes may be marketed. 
Na trgu lahko ni vseh navedenih pakiranj.
No age or gender related pharmacokinetic differences have been observed in adult patients. 
Pri odraslih bolnikih niso opazili s starostjo ali spolom povezanih farmakokinetičnih razlik.
The signs of toxicity observed in mice, rats or dogs included decreased activity, ataxia, emaciation, dehydration and tremors. 
Med znaki toksičnosti pri miših, podganah ali psih so bili zmanjšana aktivnost, ataksija, huda shujšanost, dehidracija in tremor.
In HIV-infected patients with severe immune deficiency at the time of institution of combination antiretroviral therapy (CART), an inflammatory reaction to asymtomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms. 
Pri s HIV okuženih bolnikih s hudo imunsko pomanjkljivostjo lahko ob uvedbi kombiniranega protiretrovirusnega zdravljenja (CART - combination antiretroviral therapy) nastane vnetna reakcija na asimptomatične ali rezidualne oportunistične patogene in povzroči resna klinična stanja ali poslabšanje simptomov.
Phosphodiesterase (PDE5) inhibitors 
Zaviralci fosfodiesteraze (PDE5)
What Kaletra looks like and contents of the pack 
Izgled zdravila Kaletra in vsebina pakiranja
Based on weight (mg/kg) 
Na podlagi telesne mase (mg/kg)
Antihistamines Astemizole Terfenadine 
Antihistaminiki Astemizol Terfenadin
Inhaled, injectable or intranasal fluticasone propionate, budesonide, triamcinolone 
Inhalirani, injicirani ali intranazalni flutikazonpropionat, budezonid, triamcinolon
Incremental resistance was most common in subjects whose baseline isolates had several protease inhibitor-associated mutations, but < 40-fold reduced susceptibility to lopinavir at baseline. 
Naraščajoča odpornost je bila najpogostejša pri preiskovancih, ki so imeli v izhodiščnih izolatih več mutacij, povezanih z zaviralci proteaz, toda z izhodiščno < 40-kratno zmanjšano občutljivost za lopinavir.
Cortisol levels ↓ 86% 
koncentracija v plazmi ↑ koncentracija kortizola ↓ 86%
• muscle disorders such as weakness and spasms, pain in the joints, muscles and back; 
- mišične bolezni, kot so šibkost in krči, bolečine v sklepih, mišicah in hrbtu;
(see section 4.5); - riociguat is not recommended (see section 4.5); - vorapaxar is not recommended (see section 4.5); - fusidic acid in osteo-articular infections is not recommended (see section 4.5); - salmeterol is not recommended (see section 4.5); - rivaroxaban is not recommended (see section 4.5). 
- riociguatom ni priporočljiva (glejte poglavje 4.5); - vorapaksarjem ni priporočljiva (glejte poglavje 4.5); - fusidno kislino pri osteoartikularnih okužbah ni priporočljiva (glejte poglavje 4.5); - salmeterolom ni priporočljiva (glejte poglavje 4.5); - rivaroksabanom ni priporočljiva (glejte poglavje 4.5).
Children were eligible when they were aged <18 years, ≥15 kg in weight, receiving cART that included lopinavir/ritonavir, HIV-1 ribonucleic acid (RNA) <50 copies/ml for at least 24 weeks and able to swallow tablets. 
Otroci so bili primerni, če so bili stari <18 let, so tehtali ≥15 kg, so prejemali kombinirano protiretrovirusno zdravljenje, ki je vključevalo lopinavir/ritonavir, so imeli HIV-1 ribonukleinske kisline (RNA) <50 kopij/ml najmanj 24 tednov in so bili zmožni pogoltniti tablete.
Co-administration of voriconazole and low dose ritonavir (100 mg BID) as contained in Kaletra should be avoided unless an assessment of the benefit/risk to patient justifies the use of voriconazole. 
Sočasni uporabi vorikonazola in majhnih odmerkov ritonavirja (100 mg dvakrat na dan), kot jih vsebuje zdravilo Kaletra, se je treba izogniti, razen če ocena koristi in tveganja pri bolniku upravičuje uporabo vorikonazola.
In children 14 days of age and older, the nature of the safety profile is similar to that seen in adults (see Table in section b). 
d. Pediatrična populacija Pri otrocih, starih 14 dni in več, je varnostni profil podoben kot pri odraslih (glejte preglednico v razdelku b).
A dose adjustment of Kaletra 400 mg/400 mg (i.e. Kaletra 400/100 mg + ritonavir 300 mg) twice daily has allowed compensating for the CYP 3A4 inducer effect of rifampicin. 
Prilagoditev odmerka zdravila Kaletra 400 mg/400 mg (tj. zdravilo Kaletra 400/100 mg + ritonavir 300 mg) dvakrat na dan je omogočila kompenzacijo indukcijskega učinka rifampicina na CYP3A4.
Further dosage reduction of rifabutin to 150 mg twice weekly on set days is recommended for patients in whom the 150 mg dose 3 times per week is not tolerated. 
Nadaljnje zmanjševanje odmerka rifabutina na 150 mg 2-krat na teden ob določenih dnevih je priporočljivo pri bolnikih, ki ne prenašajo odmerka 150 mg 3-krat na teden.
The combination should be used with caution and a lower dose of trazodone should be considered. 
Kombinacijo je treba uporabljati previdno; v poštev pride zmanjšanje odmerka trazodona.
The 5 bottle pack also contains five 5 ml syringes with 0.1 ml graduations. 
Pakiranje s 5 plastenkami vsebuje tudi pet 5 ml brizg z 0,1 ml oznakami.
Mechanism of interaction 
Mehanizem medsebojnega delovanja
If you or your child take more Kaletra than you should 
Če ste vi ali vaš otrok vzeli večji odmerek zdravila Kaletra, kot bi smeli
• lower respiratory tract infection; 
- okužbe spodnjih dihal;
Consequently, concomitant administration of Kaletra and these glucocorticoids is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects (see section 4.4). 
Zato sočasna uporaba zdravila Kaletra in teh glukokortikoidov ni priporočljiva, razen če možna korist zdravljenja odtehta tveganja sistemskih učinkov kortikosteroidov (glejte poglavje 4.4).
Therefore, the antiviral activity of Kaletra is due to lopinavir. 
Protivirusno delovanje zdravila Kaletra je torej posledica lopinavirja.
Lopinavir binds to both alpha-1-acid glycoprotein (AAG) and albumin however, it has a higher affinity for AAG. 
Lopinavir se veže na alfa-1-kisli glikoprotein (AKG) in na albumin, vendar ima večjo afiniteto za AKG.
• Taking Kaletra as recommended should give you the best chance of delaying the development of resistance to the product. 
- Jemanje zdravila Kaletra po navodilih zagotavlja najboljšo možnost za odložitev pojava odpornosti proti temu zdravilu.
Table 8 
Preglednica 8
The 4-oxo and 4-hydroxymetabolite epimeric pair are the major metabolites with antiviral activity, but comprise only minute amounts of total plasma radioactivity. 
Glavna presnovka s protivirusnim delovanjem sta epimerni par 4-okso- in 4-hidroksimetabolita, vendar pomenita le neznaten delež skupne radioaktivnosti v plazmi.
Resistance to lopinavir, defined as the presence of any primary or active site mutations in protease (see above), was observed in 0/51 (0%) patients. 
Odpornost proti lopinavirju, definirana kot prisotnost katerekoli primarne mutacije ali mutacije aktivnega mesta v proteazi (glejte zgoraj), je bila opažena pri 0/51 (0 %) bolnikih.
For caution on parenterally administered midazolam, see section 4.5. 
Za previdnostne ukrepe pri parenteralni uporabi midazolama glejte poglavje 4.5.
Kaletra oral solution contains up to 0.3 g of glycerol per dose. 
Peroralna raztopina zdravila Kaletra vsebuje do 0,3 g glicerola na odmerek.
At 30 weeks age of gestation, the dose was increased to 500/125 mg (two 200/50 mg tablets plus one 100/25 mg tablet) twice daily until subjects were 2 weeks postpartum. 
Pri gestacijski dobi 30 tednov je bil odmerek povečan na 500/125 mg (dve 200/50 mg tableti plus eno 100/25 mg tableto) dvakrat dnevno, do 2 tednov po porodu.
• medicines used to lower blood cholesterol (e.g. atorvastatin, lovastatin, rosuvastatin or simvastatin); 
- zdravila za zniževanje holesterola v krvi (npr. atorvastatin, lovastatin, rosuvastatin ali simvastatin);
• night sweats, itching, rash including raised bumps on the skin, infection of the skin, inflammation of skin or hair pores, accumulation of fluid in the cells or tissues. 
- nočno potenje, srbenje, izpuščaj vključno z bulami na koži, okužbe kože, vnetje kože ali lasnih por, zastajanje tekočine v celicah ali tkivih.
6/75 (8%) patients demonstrated new primary protease inhibitor mutations (codons 30, 32, 48, 50, 82, 84, 90), as did 12/77 (16%) patients in the BID group. 
V skupini, ki je prejemala zdravilo 1 x dnevno, je 6/75 (8 %) bolnikov pokazalo nove primarne mutacije proteaznih zaviralcev (kodoni 30, 32, 48, 50, 82, 84, 90), kot tudi 12/77 (16 %) bolnikov v skupini, ki je prejemala zdravilo 2 x dnevno.
Each 1 ml of Kaletra oral solution contains 356.3 mg of alcohol and 152.7 mg of propylene glycol. 
1 ml zdravila Kaletra peroralna raztopina vsebuje 356,3 mg alkohola in 152,7 mg propilenglikola.